Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial

by Patil, S.T., Zhang, L., Martenyi, F., Lowe, S.L., Jackson, K.A., Andreev, B.V., Avedisova, A.S., Bardenstein, L.M., Gurovich, I.Y., Morozova, M.A., Mosolov, S.N., Neznanov, N.G., Reznik, A.M., Smulevich, A.B., Tochilov, V.A., Johnson, B.G., Monn, J.A., Schoepp, D.D.
Published 2014

Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor

by May, P.C., Dean, R.A., Lowe, S.L., Martenyi, F., Sheehan, S.M., Boggs, L.N., Monk, S.A., Mathes, B.M., Mergott, D.J., Watson, B.M., Stout, S.L., Timm, D.E., LaBell, E.S., Gonzales, C.R., Nakano, M., Jhee, S.S., Yen, M., Ereshefsky, L., Lindstrom, T.D., Calligaro, D.O., Cocke, P.J., Greg Hall, D., Friedrich, S., Citron, M., Audia, J.E.
Published 2014